Drug-screening guided treatment before surgery for HER2 breast cancer
Part of Cancer clinical trials.
This trial tests a treatment plan that is chosen using drug-testing in a lab (to see which medicines may work best) before surgery. It is for people with early-stage HER2-positive breast cancer, aiming to improve outcomes by guiding the right treatment early.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have invasive breast cancer (not just non-invasive disease).
- Your tumor is HER2-positive (HER2 is a growth signal on the cancer).
- Your cancer is stage T2 or has spread to nearby lymph nodes.
- Your day-to-day function is good (ECOG 0 to 1, meaning you are able to care for yourself).
- Your cancer is not stage IV.
- You do not have inflammatory breast cancer.
- You do not have severe long-term health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a treatment plan chosen using lab drug testing on a patient’s tumor (in a dish). It may help improve outcomes for people with early breast cancer that is HER2-negative by matching therapy to what the tumor seems sensitive to.
This trial studies how well a HER2-focused treatment plan works before surgery (“neoadjuvant” therapy) for operable HER2-positive breast cancer. It also uses tumor tissue tests to find markers that may predict who benefits most.
This trial tests a neoadjuvant (before surgery) treatment plan for people with early-stage HER2-positive breast cancer. The goal is to see if a personalized approach can improve outcomes.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) given before surgery to shrink HER2-positive breast cancer. The goal is to see if this treatment can make the cancer disappear before surgery.
This trial tests a combination of three targeted drugs (trastuzumab, pertuzumab, and tucatinib) without chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink tumors effectively while avoiding chemotherapy side effects.
This trial tests whether giving a combination of two targeted drugs (pyrotinib and trastuzumab) along with standard chemotherapy before surgery can work better for HER2-positive breast cancer. It is for women whose cancer has not spread to distant organs and who have not yet had treatment for their cancer.
Hear when a new HER2-positive Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.